



AVHTM Newsletter

Special Events of Interest:

- **2022 ACVIM Forum Hybrid Event**
June 22-25 with limited Livestream
Austin TX
- **AVHTM SIG 2022 Dinner**
June 24; 6:00 pm CDT
FREE for AVHTM members
Please RSVP ASAP
- **IVECCS**
Sep 7-11, 2022
San Antonio TX
with AVHTM Stream on
Friday, Sep 9

(See page 4 for AVHTM topics at various conferences)

A 501(c)(3) nonprofit professional association

Volume 6, Issue 2

Welcome to the Summer AVHTM Newsletter

Welcome to the (early) Summer AVHTM Newsletter. We've got lots of great AVHTM-associated upcoming events at several major conferences, with more detail in this newsletter about our ACVIM-associated Special Interest Group dinner. We also have interesting reports from the FDA, on their role in the regulation of blood products, and Dr. Holowaychuk, on her survey of AVHTM members about their approach to blood donor medications. Dr. Holwaychuk's survey really made me think about how there are so many areas where we need more guidance in blood banking. And, to finish our newsletter off, Ken Yagi has compiled all the pertinent literature since our last newsletter.

AVHTM Presentation Topics at ACVIM Forum 2022 (on demand Jun—Oct)

- **Diagnosis and Management of Venous Thromboemboli - a Veterinary Perspective:** Marilyn Dunn (on demand)
- **Diagnosis and Management of Venous Thromboemboli - an MD's Perspective:** Stephan Moll (Friday, 24th June 1:30 pm)
- **Hunting for the Cause of a Novel Pancytopenia in Cats in the UK:** Karen Humm and Barbara Glanemann (on demand)
- **Discovery of a Novel Severe Fever and Thrombocytopenia Virus in Cats in Japan:** Claire Sharp (Friday, 24th June 2:45 pm)

AVHTM SIG June 24th 6:00 pm at Malverde Restaurant, downtown Austin
Vexing Viscoelastograms and Tricky Tranexamic Tribulations
John Thomason, Elizabeth Rozanski and Ian DeStefano

New AVHTM Website and Member Management System

We have a brand-new website at www.avhtm.org! Please take the time to peruse the site. It allows you to access information about AVHTM much more easily than previously, as well as join and renew your membership in a simpler manner. Do let us know what you think about it and if you have any suggestions for us at info@avhtm.org.

The AVHTM SIG

AVHTM will host an in-person Special Interest Group (SIG) as part of the 2022 ACVIM Forum in Austin, Texas on Friday June 24th from 6-8 PM Central Daylight Time. This will be our first in-person SIG meeting in three years, and we are looking forward to interacting with our members without having to stare at a computer screen. The SIG will be held at Malverde Restaurant in Austin, Texas, and we welcome our members to attend the meeting, eat some good food, have a few drinks, and immerse yourself in hematology and transfusion medicine. As such, we have developed an interactive session with some of our expert AVHTM speakers!

Our meeting will begin with a brief AVHTM update and followed by a discussion on interesting cases with a presentation entitled, "Vexing viscoelastograms and tricky tranexamic tribulations." This case series will include discussions on monitoring hemostasis and use of anticoagulant, antiplatelet, and antifibrinolytic therapies in dogs and cats. The session will be led by Drs. Elizabeth Rozanski, Ian DeStefano, and John Thomason. Dr. Rozanski is a diplomate of the ACVIM and ACVECC and is an associate professor at Tufts University Cummings School of Veterinary Medicine. Dr. DeStefano is a diplomate of ACVECC and is a clinical assistant professor at Tufts University Cummings School of Veterinary Medicine. Dr. Thomason is a diplomate of ACVIM and is an associate professor at Mississippi State University College of Veterinary Medicine. We look forward to seeing everyone there!

SIG sponsorship is graciously provided by [Entegriion](#).

If you plan to attend, please RSVP via info@avhtm.org so we can keep the restaurant apprised of our numbers. We do have a 50-person limit. If you already RSVPed through ACVIM, please still send us an email.



This is a FREE dinner for AVHTM members!

Blood Donor Medication Survey: January 2022

By: Marie K. Holowaychuk, DVM, Dipl. ACVECC

Controversy persists regarding whether to accept canine donors who are given medications for chronic health conditions. There are no firm consensus guidelines and very little in the way of research investigating this in veterinary medicine.

Therefore, in January of this year, a survey link was distributed to the AVHTM Google Group to solicit responses regarding enrolment or exclusion of canine donors based on whether they are being given certain medications. Thirty-eight responses were obtained and demonstrated some interesting findings.

More than half (55%) of respondents exclude canine donors that are receiving a daily thyroid supplement. When asked about permitting canine donors that receive over-the-counter antihistamines for well-controlled allergies, 45% exclude them, 45% accept them, and 10% use them under extenuating circumstances.


While 71% of respondents exclude canine donors that receive Apoquel® chronically for well-controlled allergies, 74% of respondents permit a return to donation for dogs that receive Apoquel® for an allergic episode with 35% utilizing them after 14 days and 25% after 1 month.

In comparison, 63% of respondents exclude canine donors that have received Cytopoint® for an allergic episode. Of the respondents who permit canine donors that received Cytopoint® for an allergic episode to return to donation, 30% impose a "washout period" of 1 month.

Other mentioned permissible medications include behavioural or sedative medications (e.g., trazodone, gabapentin, fluoxetine, sertraline) and joint supplements (e.g., EFAs, glucosamine, chondroitin sulfate).

When asked about canine donors that consume raw food as part of or their entire diet, 58% of respondents exclude them.

Thank you to those who took the time to participate in this survey! To view the complete results, please visit: <https://forms.gle/JreGxoK9H9txU8u4A>.



teviot
TECHNOLOGIES

Unlock New Possibilities

Introducing the only company dedicated to supporting Veterinary Transfusion Medicine. Our TT-VET Apheresis Device streamlines the collection process from a wide range of mammals so you can focus on saving lives.

Learn more at [TeviotTech.com](https://www.teviotech.com)

Veterinary Blood and Blood Components: FDA Regulation, Review, and Monitoring

Veterinary blood and blood components (blood products) for transfusion are regulated by FDA as new animal drugs. Although veterinary blood products currently have the same regulatory requirements as traditional chemical entities, we, FDA, recognize that there are differences in the considerations relevant to these products.

Blood products for transfusion are one example of animal cells, tissues, and cell- and tissue-based products (ACTPs). As described in [Guidance for Industry 218](#), FDA recognizes that certain ACTPs may pose a lower risk to human and animal safety than other types of animal drug products. In certain situations, FDA may conduct a product-specific review of an ACTP such as a veterinary blood product to determine if the product is low risk and therefore, a lower agency enforcement priority.

Whether an ACTP is approved or has been determined to be low risk, we still expect manufacturers of these products to report adverse events to FDA and comply with other manufacturing and post-marketing responsibilities. We also encourage veterinarians to report adverse events associated with all drugs and devices used in animals, including veterinary blood and blood components as well as other ACTPs. For information on reporting, see [Report a Problem](#).

FDA encourages the development of blood products and other ACTPs. We established the [Veterinary Innovation Program](#) to facilitate advancements in development of innovative products and created [a listing of clinical field studies that are investigating ACTPs in veterinary patients](#). We issued guidance for industry pertaining to the development, [donor eligibility](#), and [manufacturing](#) of ACTPs. We are also working on a proposal for regulating ACTPs that would establish current animal good tissue practice for ACTPs.

FDA has recently been conducting outreach efforts to those with experience in veterinary blood banking so that we may stay informed of the concerns and impacts faced by this industry. To ask questions, request additional information related to the content of this article, or provide feedback, please reach out to us at FDA-CVM-Animal-Biotechnology-Feedback@fda.hhs.gov.

Join us for our Annual SIG, June 24, 6:00 pm

Malverde Restaurant
400b W 2nd St, Austin TX

RSVP directly when you register with ACVIM or email us at info@avhtm.org

Upcoming AVHTM Topics

ACVIM Forum Hybrid Event June 22—25 2022

Austin, Texas with limited Livestream

On Demand June- October

With AVHTM Stream:

- Diagnosis and Management of Venous Thromboemboli - a Veterinary Perspective: Marilyn Dunn (on demand)
- Diagnosis and Management of Venous Thromboemboli - an MD's Perspective: Stephan Moll (Friday 24th June 13.30)
- Hunting for the Cause of a Novel Pancytopenia in Cats in the UK: Karen Humm and Barbara Glanemann (on demand)
- Discovery of a Novel Severe Fever and Thrombocytopenia Virus in Cats in Japan: Claire Sharp (Friday 24th June 14.45)



IVECCS September 7—11 2022

San Antonio, Texas

With AVHTM stream (Friday 9th September):

- Crossmatching: Ins, Outs and Controversies: Sarah Musulin
- Approach to the Anemic Cat: Rebecca Walton
- Anti-platelet Therapy: What is Safe and Effective: John Thomason
- War Dogs: Case Reports on our 4-legged Heroes: Thomas Edwards
- Plasma and Albumin Transfusions: Erin Mays
- The Future of Transfusion Medicine: Erin Mays

Recently Published Articles

- **A novel autotransfusion device saving erythrocytes and platelets used in a 72 h survival swine model of surgically induced controlled blood loss.** Schreiber K, Decouture B, Lafrayette A, Chollet S, Bruneau M, Nicollet M, Wittmann C, Gadrat F, Mansour A, Forest-Villegas P, Gauthier O, Touzot-Jourde, G. PLoS One. 2022 Mar 24;17(3)
- **Hemoglobin-Based Oxygen Carrier for the Reconstitution of Canine Freeze-Dried Plasma in an In Vitro Model of Resuscitation.** Edwards TH, Meledeo MA, Peltier GC, Henderson AF, Hammill RM, McIntosh CS, Bynum JA. J Spec Oper Med. 2022 Spring;22(1):111-114.
- **Feline blood donation adverse reactions: classification and description of acute and delayed reactions in a donor population.** Abreu TA, Oliveira AS, Ferreira RR, Correia SM, Moraes MS, Soares R, Flamínio M, Mesa-Sanchez I, Gopegui RR, de Matos AJ. J Feline Med Surg. 2022 Apr;24(4):284-289.
- **Xenotransfusion of Blood from Dog to Cat: Should Canine Blood Be Our First Choice for Feline Transfusion in Emergency Situations.** Deschamps JY, Abboud N, Roux FA. Vet Sci. 2022 Feb 28;9(3):106. PMID: 35324834 Free PMC article.
- **Characterization of post-transfusion anti-FEA 1 alloantibodies in transfusion-naïve FEA 1-negative cats.** Cannavino A, LeVine D, Blais MC. J Feline Med Surg. 2022 Online ahead of print.
- **The effect of position and frequency of mixing on canine packed red blood cell units during storage.** Aumann SM, Reems MM. J Vet Emerg Crit Care (San Antonio). 2022 Mar;32(2):181-188.
- **Looking for Dog Blood Donors in an Endemic Area for Vector-Borne Infections of Central Italy.** Antognoni MT, Vascellari M, Da Rold G, Toniolo F, Sgubin S, Zanardello C, Carminato A, Miglio A. Animals (Basel). 2022 Mar 23;12(7):817.
- **Centrifugal therapeutic plasma exchange in dogs with immune-mediated hemolytic anemia (2016-2018): 7 cases.** Culler CA, Vigani A, Ripoll AZ, Gareau A, Suter SE. J Vet Emerg Crit Care (San Antonio). 2022 Online ahead of print.
- **Therapeutic plasma exchange for the management of a type III hypersensitivity reaction and suspected immune-mediated vasculitis assumed to be caused by human albumin administration in a dog.** Klainbart S, Segev G, Kelmer E, Chen H. J Vet Emerg Crit Care (San Antonio). 2022 Online ahead of print.



We're on the web!

www.avhtm.org

AVHTM

PO Box 1234
Sahuarita AZ 85629-1004

Email: info@avhtm.org

AVHTM is an IRS approved 501(c)(3) nonprofit professional association composed of veterinarians, hematologists, academics, veterinary technicians, blood bankers, and interested public who desire to further scientific advances in transfusion medicine and veterinary hematology.

We engage in veterinary research, promote industry standards, develop guidelines for canine and feline blood collection and processing, and publish scientific research in peer-reviewed publications.

Visit us online to learn more about AVHTM!

MEMBERSHIP BENEFITS

As an AVHTM member, you are eligible for the following:

- Reduced IVECCS registration fee (veterinarians save \$100 and technicians save \$25!)
- Access the a "Members Only" section of the AVHTM website, which includes access to:
 - o Other AVHTM profiles
 - o PubMed articles
 - o Forum for posting questions, cases, and research
- Ability to ask and answer questions posted to the AVHTM members-only Google group.

Please feel welcome to share this newsletter with interested colleagues and encourage them to become an AVHTM member!